Developer docs
API playgroundTry for free, no card

Search company profiles

SynapCell

Full company profile

uuid000jvlh

Namestring
SynapCell
Legal namestring
SynapCell
Websiteurl
synapcell.fr
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSaint-ismier, France
HQ citystring
Saint-ismier
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
preclinical CRO services, EEG biomarker analysis, CNS drug discovery, rodent model testing, epilepsy research services
Industry1 code
SECONDARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Fee-for-service contract research organization providing preclinical EEG testing services to pharmaceutical and biotech companies. Revenue is generated through project-based contracts for drug efficacy testing, pharmaco-EEG studies, de-risking studies, and model exploration. Services are tailored to client-specific protocols and compound profiles.

synapcell.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom Project-Based Pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Each project is quoted individually based on study requirements. No standardized tiers or public pricing available.

synapcell.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Cue®
Description

SynapCell's translational and predictive in vivo EEG platform designed to predict in-human efficacy of drug candidates during preclinical steps. Cue® combines know-how, expertise, and scientific excellence in brain surgery and EEG signal recording, processing, and analysis.

synapcell.com
Core offering1 text field

SynapCell is a preclinical Contract Research Organization providing EEG-based CNS drug discovery services for pharmaceutical and biotechnology companies. Its core deliverable is the CUE® translational in vivo EEG platform, applied through customized rodent-model studies and EEG biomarker analysis to predict in-human efficacy of drug candidates for epilepsy, movement disorders, psychiatric conditions, and rare diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Predictive preclinical-to-human translation of drug efficacy for CNS compounds
+1 more record
Product overview1 text field

SynapCell is a preclinical Contract Research Organization (CRO) specializing in EEG services for CNS drug discovery. The company operates a platform-plus-services model centered on CUE®, their proprietary translational in vivo EEG platform. Services include Drug Efficacy Testing, Pharmaco-EEG, Sleep & Vigilance States, Model Exploration, De-risking, Collaborative Projects, and Remote Preclinical EEG Laboratory services. The company focuses on select therapeutic areas: Epilepsy (Focal, Absence, Focal-to-Generalized), Movement Disorders (Parkinson's Disease, Essential Tremor), Rare Disorders (Autism, Tauopathy), and Psychiatric Disorders (Schizophrenia, Anxiety and Agitation).

Product and service8 records
1CUE® Platform
CategoryCore technology platform
Description

SynapCell's translational and predictive in vivo EEG platform that processes preclinical rodent models and their associated EEG biomarkers to predict in-human efficacy of drug candidates during preclinical stages. Used by pharmaceutical and biotechnology companies for CNS drug discovery decision-making.

2Drug Efficacy Testing
CategoryPreclinical CRO service
Description

Preclinical assay service for testing drug efficacy in rodent models targeting CNS disorders including epilepsy, movement disorders, psychiatric conditions, and rare diseases. Provided to pharma and biotech clients as a customized study engagement.

3Pharmaco-EEG
CategoryPreclinical CRO service
Description

Preclinical EEG service for assessing the pharmacodynamic effects of compounds on brain electrical activity. Used by pharma and biotech teams evaluating CNS drug candidates.

4Sleep & Vigilance States
CategoryPreclinical CRO service
Description

Preclinical EEG capability for characterizing compound effects through information on sleep and wakefulness states, providing additional insights beyond standard efficacy testing. Aimed at pharma and biotech teams seeking differentiated CNS compound characterization.

5Model Exploration
CategoryPreclinical CRO service
Description

Service for exploring and validating preclinical rodent models for CNS drug discovery, helping clients identify the most appropriate disease model for their compound.

6De-risking
CategoryPreclinical CRO service
Description

Risk assessment service for preclinical CNS drug development programs, helping clients reduce the risk of late-stage clinical failure by validating efficacy and translatability early.

7Collaborative Projects
CategoryPreclinical CRO service
Description

Co-development partnership model where SynapCell collaborates with clients on neuroscience research projects, acting as an extension of the client's research team from conceptualization to conclusion.

8Remote Preclinical EEG Laboratory
CategoryPreclinical CRO service
Description

Outsourced preclinical EEG laboratory service providing facilities, expertise, translational rodent models, and EEG biomarkers without in-house investment requirements. Functions as a long-term partner familiar with the client's protocols and constraints.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Celebration of the 10-year anniversary of collaboration on anti-seizure medications. The partnership has focused on joint research and development efforts for anti-seizure medications, demonstrating a sustained academic-industry collaboration that has produced scientific publications and advanced epilepsy drug discovery.

2Client Research Teams
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SynapCell positions itself as a collaborative partner rather than a transactional vendor, functioning as an extension of client research teams. The company co-develops projects with clients, providing end-to-end support from conceptualization through conclusion, translating raw EEG data into actionable insights.

synapcell.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based preclinical CRO with deep CNS expertise including EEG/electrophysiology and translational biomarker discovery. Direct peer in offering specialized in vivo CNS services to pharma with proprietary platforms and rodent disease models.

TypeBroad incumbent
Description

Global CRO/CDMO with growing preclinical CNS and translational services capacity. Represents the scale-incumbent competitive threat, particularly for clients seeking integrated discovery-to-development partners.

TypeEmerging player
Description

US-based preclinical CRO expanding into biologics and complex therapeutics testing. Adjacent competitor for early-stage biotech preclinical outsourcing budgets where CNS and specialty pharmacology buyers overlap.

TypeBroad incumbent
Description

US-based preclinical CRO offering discovery, safety assessment, and research models including CNS programs. Comparable as a broad preclinical competitor addressing similar pharma buyers across multiple modalities.

TypeEmerging player
Description

JSR-owned preclinical CRO with translational oncology and CNS disease models. Comparable as a growing specialty CRO targeting translational drug discovery outsourcing budgets with proprietary platform offerings.

6Brains On-Line
TypeDirect peer
Description

Netherlands-based preclinical CRO focused on in vivo EEG and CNS pharmacology in rodent models. Highly comparable as a specialized EEG CRO serving pharma CNS drug discovery, though with a different geographic footprint.

TypeBroad incumbent
Description

Global CRO offering preclinical and clinical CNS services through its drug development business. Comparable as a full-service incumbent competing for the same pharma outsourcing RFPs SynapCell targets.

TypeBroad incumbent
Description

Global preclinical CRO with extensive CNS capabilities including EEG and translational biomarker services. Competes for the same pharma outsourcing budgets as SynapCell but as part of a much broader discovery and safety portfolio.

TypeDirect peer
Description

French-headquartered preclinical CRO specializing in CNS and behavioral pharmacology models. Highly comparable to SynapCell in geography, customer base (pharma/biotech CNS programs), and contract research services model, though Porsolt's core is behavioral rather than EEG-based.

TypeBroad incumbent
Description

Large discovery services arm of Eurofins offering preclinical pharmacology including CNS indications. Represents the broad incumbent alternative for pharma sponsors comparing specialist CROs against full-service providers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SynapCell

Preclinical Contract Research Servicessynapcell.fr

SynapCell firmographics

Firmographics
Name
SynapCell
Legal name
SynapCell
Website
https://synapcell.fr
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Where SynapCell is headquartered

Location

Headquarters

HQ city
Saint-ismier
HQ country
France
HQ region
Europe

Markets served

SynapCell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Preclinical Contract Research Services: Fee-for-service contract research organization providing preclinical EEG testing services to pharmaceutical and biotech companies. Revenue is generated through project-based contracts for drug efficacy testing, pharmaco-EEG studies, de-risking studies, and model exploration. Services are tailored to client-specific protocols and compound profiles.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Project-Based Pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

SynapCell product offering

Product offering

Core offering

SynapCell is a preclinical Contract Research Organization providing EEG-based CNS drug discovery services for pharmaceutical and biotechnology companies. Its core deliverable is the CUE® translational in vivo EEG platform, applied through customized rodent-model studies and EEG biomarker analysis to predict in-human efficacy of drug candidates for epilepsy, movement disorders, psychiatric conditions, and rare diseases.

Product overview

SynapCell is a preclinical Contract Research Organization (CRO) specializing in EEG services for CNS drug discovery. The company operates a platform-plus-services model centered on CUE®, their proprietary translational in vivo EEG platform. Services include Drug Efficacy Testing, Pharmaco-EEG, Sleep & Vigilance States, Model Exploration, De-risking, Collaborative Projects, and Remote Preclinical EEG Laboratory services. The company focuses on select therapeutic areas: Epilepsy (Focal, Absence, Focal-to-Generalized), Movement Disorders (Parkinson's Disease, Essential Tremor), Rare Disorders (Autism, Tauopathy), and Psychiatric Disorders (Schizophrenia, Anxiety and Agitation).

Differentiator

Problem solved

Functional benefit

Brands

  • Cue®: SynapCell's translational and predictive in vivo EEG platform designed to predict in-human efficacy of drug candidates during preclinical steps. Cue® combines know-how, expertise, and scientific excellence in brain surgery and EEG signal recording, processing, and analysis.

Products and services

  • CUE® Platform SynapCell's translational and predictive in vivo EEG platform that processes preclinical rodent models and their associated EEG biomarkers to predict in-human efficacy of drug candidates during preclinical stages. Used by pharmaceutical and biotechnology companies for CNS drug discovery decision-making.
  • Drug Efficacy Testing Preclinical assay service for testing drug efficacy in rodent models targeting CNS disorders including epilepsy, movement disorders, psychiatric conditions, and rare diseases. Provided to pharma and biotech clients as a customized study engagement.
  • Pharmaco-EEG Preclinical EEG service for assessing the pharmacodynamic effects of compounds on brain electrical activity. Used by pharma and biotech teams evaluating CNS drug candidates.
  • Sleep & Vigilance States Preclinical EEG capability for characterizing compound effects through information on sleep and wakefulness states, providing additional insights beyond standard efficacy testing. Aimed at pharma and biotech teams seeking differentiated CNS compound characterization.
  • Model Exploration Service for exploring and validating preclinical rodent models for CNS drug discovery, helping clients identify the most appropriate disease model for their compound.
  • De-risking Risk assessment service for preclinical CNS drug development programs, helping clients reduce the risk of late-stage clinical failure by validating efficacy and translatability early.
  • Collaborative Projects Co-development partnership model where SynapCell collaborates with clients on neuroscience research projects, acting as an extension of the client's research team from conceptualization to conclusion.
  • Remote Preclinical EEG Laboratory Outsourced preclinical EEG laboratory service providing facilities, expertise, translational rodent models, and EEG biomarkers without in-house investment requirements. Functions as a long-term partner familiar with the client's protocols and constraints.

Quantifiable outcome

  • Predictive preclinical-to-human translation of drug efficacy for CNS compounds
  • +1 more outcomes

Companies that use SynapCell

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles3 records

SynapCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

SynapCell partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • University of UtahcoreStrategic or Co-development Partner · 1 January 2024Celebration of the 10-year anniversary of collaboration on anti-seizure medications. The partnership has focused on joint research and development efforts for anti-seizure medications, demonstrating a sustained academic-industry collaboration that has produced scientific publications and advanced epilepsy drug discovery.
  • Client Research TeamscoreStrategic or Co-development PartnerSynapCell positions itself as a collaborative partner rather than a transactional vendor, functioning as an extension of client research teams. The company co-develops projects with clients, providing end-to-end support from conceptualization through conclusion, translating raw EEG data into actionable insights.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

SynapCell competitors and assessment

Company assessment

Direct peers

  • PsychoGenics: US-based preclinical CRO with deep CNS expertise including EEG/electrophysiology and translational biomarker discovery. Direct peer in offering specialized in vivo CNS services to pharma with proprietary platforms and rodent disease models.
  • Brains On-Line: Netherlands-based preclinical CRO focused on in vivo EEG and CNS pharmacology in rodent models. Highly comparable as a specialized EEG CRO serving pharma CNS drug discovery, though with a different geographic footprint.
  • Porsolt: French-headquartered preclinical CRO specializing in CNS and behavioral pharmacology models. Highly comparable to SynapCell in geography, customer base (pharma/biotech CNS programs), and contract research services model, though Porsolt's core is behavioral rather than EEG-based.

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO with growing preclinical CNS and translational services capacity. Represents the scale-incumbent competitive threat, particularly for clients seeking integrated discovery-to-development partners.
  • Inotiv: US-based preclinical CRO offering discovery, safety assessment, and research models including CNS programs. Comparable as a broad preclinical competitor addressing similar pharma buyers across multiple modalities.
  • Labcorp Drug Development: Global CRO offering preclinical and clinical CNS services through its drug development business. Comparable as a full-service incumbent competing for the same pharma outsourcing RFPs SynapCell targets.
  • Charles River Laboratories: Global preclinical CRO with extensive CNS capabilities including EEG and translational biomarker services. Competes for the same pharma outsourcing budgets as SynapCell but as part of a much broader discovery and safety portfolio.
  • Eurofins Discovery: Large discovery services arm of Eurofins offering preclinical pharmacology including CNS indications. Represents the broad incumbent alternative for pharma sponsors comparing specialist CROs against full-service providers.

Emerging players

  • Bionova Scientific: US-based preclinical CRO expanding into biologics and complex therapeutics testing. Adjacent competitor for early-stage biotech preclinical outsourcing budgets where CNS and specialty pharmacology buyers overlap.
  • Crown Bioscience: JSR-owned preclinical CRO with translational oncology and CNS disease models. Comparable as a growing specialty CRO targeting translational drug discovery outsourcing budgets with proprietary platform offerings.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

SynapCell social profiles

Digital presence

SynapCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SynapCell leadership team

Management profile

Number of profiles

Profiles4 records

SynapCell funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SynapCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SynapCell

What does SynapCell do?

SynapCell is a preclinical Contract Research Organization providing EEG-based CNS drug discovery services for pharmaceutical and biotechnology companies. Its core deliverable is the CUE® translational in vivo EEG platform, applied through customized rodent-model studies and EEG biomarker analysis to predict in-human efficacy of drug candidates for epilepsy, movement disorders, psychiatric conditions, and rare diseases.

When was SynapCell founded?

SynapCell was founded in 2004. It employs 11 to 50 people.

Where is SynapCell based?

SynapCell is headquartered in Saint-ismier, France, in the Europe region.

How does SynapCell make money?

One revenue line is on record: preclinical Contract Research Services.

Who are SynapCell's main competitors?

Direct peers on record are PsychoGenics, Brains On-Line and Porsolt. Broad incumbents are WuXi AppTec, Inotiv, Labcorp Drug Development, Charles River Laboratories and Eurofins Discovery. Emerging players are Bionova Scientific and Crown Bioscience.

Does SynapCell have an API?

No public API is recorded for SynapCell.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals